Company intelligence / Profile preview

Langyu Pharmaceutical Technology

Shanghai, Shanghai, China

Ownership: Private
Development stage: Other

Overview

Langyu Pharmaceutical is a clinical-stage biotechnology company based in Shanghai, China, focused on the development of innovative small molecule drugs using protein degradation technologies. The company utilizes its proprietary platform to design molecular glues and PROTACs that target proteins previously considered undruggable. Its lead candidate, LY-001, is a GSPT1 degrader currently in Phase 1 clinical trials for various cancers. Langyu is backed by prominent venture capital firms and aims to provide transformative therapies for oncology and autoimmune diseases.

Therapeutic areas: Oncology
Modalities: Small moleculeMolecular glue therapyProteolysis-targeting chimera therapy
Industry: Biotech

Drug pipeline

1 asset

JKN23051

Unknown

Beyond the preview

Go deeper on Langyu Pharmaceutical Technology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Langyu Pharmaceutical Technology.

Explore the full profile